|
|
SCIENTIFIC ADVISORY BOARD
 John E. Hearst, Ph.D., University of California, Berkeley
John E. Hearst, PhD, is a co-founder of Cerus Corporation and served on the Cerus BOD from 1990 to 2001. Dr. Hearst was a Professor of Chemistry at the University of California at Berkeley for over 35 years.
He is an expert on nucleic acid chemistry and has published more than 300 peer review scientific papers and more than 25 issued patents on transcription, translation, psoralen photochemistry, DNA excision repair, photosynthesis, and DNA structure and elasticity.
 Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon), University of California, San Francisco
Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) is the Director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and clinical care organization that is one of the largest cancer centers in the Western United States, and he is Associate Dean of the UCSF School of Medicine. A native of Cambridge, England, Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham (1972) and his Ph.D. in biochemistry from the University of Cambridge (1975). Postdoctoral fellowships were held in the US at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund.
He has been a Fellow of the Royal Society since 1996. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms, including positions with Cetus Corporation (Director of Molecular Biology, 1981-90; Vice President of Research, 1990-91) and Chiron Corporation, where he was Vice President of Research from 1991-92.
In 1992 he founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. Dr. McCormick's current research interests center on the fundamental differences between normal cells and cancer cells that can allow the development of novel therapeutic strategies.
In addition to his positions as Director of the UCSF Helen Diller Family Comprehensive Cancer Center and Associate Dean of the UCSF School of Medicine, he holds the E. Dixon Heise Distinguished Professorship in Oncology and the David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research in UCSF's Department of Microbiology and Immunology. Dr. McCormick is the author of more than 260 scientific publications.
 Daniel A. Portnoy, Ph.D., University of California, Berkeley
Dr. Portnoy is a Professor at UC Berkeley with joint appointments in the Divisions of Biochemistry & Molecular Biology, Immunology and Pathogenesis, Infectious Diseases, and Microbial Biology. He is also the Associate Director of the Berkeley Center for Emerging and Neglected Diseases. Dr. Portnoy carried out his doctoral studies at the University of Washington and Stanford, and postdoctoral studies at Rockefeller University. He has held faculty positions at Washington University and the University of Pennsylvania.
He has published over 100 papers in the areas of microbial pathogenesis and recently co-authored the section on L. monocytogenes in Harrison's Principles of Internal Medicine. Dr. Portnoy has served on Editorial Boards for Infection & Immunity, Journal of Experimental Medicine, Annual Review of Cell and Developmental Biology, Cellular Microbiology, Molecular Microbiology and PLoS Pathogens.
Dr. Portnoy studies the microbiology and immunology of intracellular pathogens with a focus on the pathogenesis of Listeria monocytogenes. He is an expert on L. monocytogenes genetics, cell biology, and immunobiology and his lab was instrumental in the development of L. monocytogenes as a vector for cancer vaccines.
Dr. Portnoy has received numerous awards and honors including the Eli Lilly and Company Research Award in Microbiology & Immunology, NIH Merit Award, Gordon Conference Chair, Honorary Doctoral from Sweden, Fellow, American Academy of Microbiology, Senior Scholar Award in Global Infectious Diseases from the Ellison Foundation, and numerous honorary keynote lectures.
 Mike Powell, Ph.D., Sofinnova Ventures
Mike Powell, Ph.D., is an Advisor to Aduro. Dr. Powell has more than 25 years of pharmaceutical development experience, and he has focused interest in clinical-stage product companies, particularly in the oncology, endocrine, and neurology areas. He joined Sofinnova Ventures as a General Partner in 1997 as a member of the Life Science investment team.
Prior to becoming a venture capitalist, Mike worked on 20 clinical products and authored almost 100 papers and books, including a 1,000-page treatise on vaccine design.
|